Bristol Myers Squibb’s (BMS) dual immunotherapy combination has been recommended by the European Medicines Agency’s human ...

The CHMP recommends approval of Bristol Myers' Opdivo plus Yervoy for the first-line treatment of hepatocellular carcinoma ...

A sensation of fullness beneath the ribs on the right side A similar feeling under the ribs on the left side Yellowing of the ...

Hepatocellular carcinoma (HCC) is a prevalent malignant cancer worldwide ... peptide-specific TCR-engineered T cells are unlikely to cause severe off-target toxicity (88). AFP peptide-based CAR-T ...

Squibb announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended ...

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector. Baird analyst ...

PRINCETON, N.J. - Bristol Myers Squibb (NYSE: BMY), a prominent pharmaceutical company with a market capitalization of nearly $120 billion and impressive gross profit margins of 76%, received a ...

T-cells from the liver and lymph nodes show promising potential for future treatments of liver cancer, according to a new ...

Fujifilm Middle East and Africa part of the globally renowned Fujifilm Corporation is participating at Arab Health 2025 ...

Bristol Myers on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Breyanzi for the treatment of adults with relapsed or refractory ...